Financial Performance - The net profit for the third quarter of 2023 reached CNY 144,514,979.02, a significant increase of 83.83% compared to CNY 78,551,187.11 in the same period last year[3] - The company reported an operating profit of CNY 171,168,058.78, which is a 83% increase from CNY 93,606,855.47 in the previous year[3] - Operating revenue increased by 56.93% to CNY 542,445,746.24 from CNY 345,656,815.72 in the same period last year[31] - Total operating revenue for the third quarter reached ¥542,445,746.24, a significant increase from ¥345,656,815.72 in the same period last year, representing a growth of approximately 56.9%[43] - Basic and diluted earnings per share for the quarter were both ¥0.50, compared to ¥0.27 in the previous year, reflecting an increase of approximately 85.2%[39] - The net profit attributable to shareholders for the current period is CNY 31,476,110.61, reflecting a 30.32% increase year-over-year[48] - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 30,899,063.90, which is a 45.57% increase compared to the previous year[48] Assets and Equity - The total assets as of September 30, 2023, amounted to CNY 2,498,883,170.39, slightly up from CNY 2,497,721,443.51 at the beginning of the year[1] - The company's total equity attributable to shareholders increased to CNY 2,326,723,462.93 from CNY 2,276,499,452.63, reflecting a growth of 2.2%[1] - Non-current assets totaled CNY 379,696,150.53, while total assets reached CNY 2,498,883,170.39, compared to CNY 270,826,069.16 and CNY 2,497,721,443.51 respectively in the previous year[19] - The total assets at the end of the reporting period amount to CNY 2,498,883,170.39, a slight increase of 0.05% from the end of the previous year[48] - The equity attributable to shareholders at the end of the reporting period is CNY 2,326,723,462.93, which is a 2.21% increase from the previous year[48] Cash Flow - Cash and cash equivalents at the end of the third quarter were CNY 1,729,396,597.93, down from CNY 1,858,088,871.05 at the beginning of the year, indicating a decrease of 6.9%[5] - Cash flow from operating activities decreased by 32.99% to CNY 82,988,321.06, primarily due to significant pre-receipts in December 2022[31] - The net cash flow from operating activities for the year-to-date is CNY 82,988,321.06, showing a decrease of 32.99% compared to the same period last year[48] - The cash inflow from investment activities for the current period is CNY 377,510.89, compared to CNY 63,000.00 in the previous period[48] Expenses - R&D expenses surged by 131.24% to CNY 34,932,093.15, driven by the company's integrated strategy of "raw materials + formulations" and progress in consistency evaluation[31] - Total operating costs amounted to ¥374,327,664.34, up from ¥261,859,834.81, indicating an increase of about 42.7% year-over-year[43] - Tax expenses for the quarter were ¥4,467,473.08, up from ¥2,280,330.08, representing an increase of approximately 96.2% year-over-year[43] - Sales expenses increased to ¥17,471,902.46 from ¥13,790,374.69, reflecting a rise of about 26.5%[43] - Management expenses decreased slightly to ¥35,340,769.90 from ¥37,409,148.74, showing a reduction of approximately 5.5%[43] Shareholder Information - The company’s total number of common shareholders at the end of the reporting period was 24,588[33] - The largest shareholder, Shanghai Yongda Sheng Business Consulting Co., Ltd., holds a 38.25% stake, amounting to 110,160,000 shares[33] Liabilities - The total liabilities amounted to CNY 172,159,707.46, compared to CNY 221,221,990.88 in the previous year[19] - Contract liabilities decreased by 81.79% to CNY 12,692,792.18 from CNY 69,720,405.61 in the previous year[31] Audit Status - The company has not undergone an audit for the third quarter report[24]
亨迪药业(301211) - 2023 Q3 - 季度财报